Cellcyte Genetics Corporation
1725-220th Street SE
Suite 103
Bothell,
WA 98021
United States - Map
Phone: 425-483-6101
Fax: 425-483-1741
Web Site: http://www.cellcyte.com
| Cellcyte Genetics Corporation, a development stage biotechnology company, engages in the discovery and development of stem cell enabling therapeutic products and medical devices for cell production. The companys development-stage products include CCG-TH30, a ligand for liver targeting the heart of normal nonobese diabetes/severe combined immunodeficiency (NOD/SCID) mice; and CCG-TH35 to enhance the delivery of mesenchymal stem cells to the heart of normal NOD/SCID mice. It also involves in the research and development of a cell expansion and maintenance device that is based on superior oxygenation, which allows cells to expand and completely fill the bioreactor with viable cells; and stem cell purification platform, a stem cell purification technology based on a proven immunoaffinity capture system for stem cells that was previously used with cancer patients. The company was founded in 2005 and is based in Bothell, Washington. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. John Fluke Jr., 66
Interim Chief Exec. Officer, Independent Director and Chairman of Audit Committee |
$
0 | N/A | Mr. Randy A. Lieber CPA, 52
Principal Accounting Officer |
$
0 | N/A | Mr. Mark Reys ,
VP of Operations |
N/A
| N/A | Dr. H. Andreas Kalmes Ph.D.,
Head of Art Nuclear Imaging Unit and VP of Pharmacology |
N/A
| N/A | Dr. Jay H. Traverse M.D., FACC, FAHA,
Clinical Consultant and Member of Scientific Advisory Board |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
1.00% Nasdaq 
0.0032 (10.00%) 
Profile
